AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

HCM · NASDAQ · Drug Manufacturers - Specialty & Generic

HUTCHMED (ADR) (HCM)

Develops targeted therapies and immunotherapies, commercializing medicines in China and through global partners.

$14.21

vs last close+0.14 (+0.96%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	153	153	153	153	162	162	139	139	135	135	139	139
Cost of revenue	167	239	90	90	190	190	84	84	159	159	115	115
Gross profit	−86	−86	63	63	−28	−28	55	55	−23	−23	24	24
	−40	−40	77	77	−20	−20	57	57	−5	−5	23	23
Research & development	79	79	48	48	59	59	36	36	41	41	39	39
	32	32	29	29	28	28	21	21	31	31	23	23
Selling & marketing	13	27	14	14	11	11	7	7	11	11	7	7
General & administrative	19	6	15	15	17	17	14	14	19	19	16	16
Other expenses	−152	−152	0	0	−107	−107	0	0	−77	−77	−39	−39
Operating income	−47	−47	−14	−14	−8	−8	−2	−2	−18	−18	0	0
	13	13	28	28	16	16	261	261	19	19	8	8
Interest income	18	18	0	0	19	19	0	0	0	0	0	0
Income before tax	−33	−33	15	15	8	8	259	259	1	1	9	9
Income tax expense	1	1	1	1	2	2	32	32	0	0	1	1
Net income from continuing operations	−34	−34	13	13	6	6	228	228	1	1	8	8
Net income	−34	−34	13	13	6	6	227	227	1	1	8	8
EPS, basic	−$0.20	−$0.20	$0.08	$0.08	$0.04	$0.04	$1.30	$1.30	$0.01	$0.00	$0.05	$0.05
EPS, diluted	−$0.20	−$0.20	$0.07	$0.07	$0.04	$0.04	$1.30	$1.30	$0.01	$0.01	$0.05	$0.05
Weighted average shares, basic	170	170	172	172	175	175	175	175	173	172	173	173
Weighted average shares, diluted	170	170	175	175	175	175	175	175	175	175	175	175
EBITDA	−44	−44	−11	−11	−5	−5	1	1	−14	−14	4	4
Depreciation & amortization	2	2	3	3	3	3	3	3	4	4	4	4
EBIT	−47	−47	−14	−14	−8	−8	−2	−2	−18	−18	0	0